Introduction: Immunity of colitis-associated colorectal cancer (CAC) differs fundamentally from that of the sporadic form. The aim of this study was to evaluate whether this difference could potentiate the efficacy of immune-checkpoint inhibitor anti-PD1 against CAC.
No takes yet. Share an insight, caveat, or question.
Collard et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: